Awaiting product image

Article: O.4 SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma

€2.42

SKU: product-article-18262 Category:

Description

O.4 SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma

Reviews

There are no reviews yet.

Be the first to review “Article: O.4 SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma”

Your email address will not be published. Required fields are marked *

Related products